SW · LLY.SW
Eli Lilly and Company
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Indianapolis, IN 46285
- Website
- lilly.com
Price · as of 2025-12-31
$685.00
Market cap 693.45B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $387.50 | -43.43% |
| Intrinsic Value(DCF) | $990.27 | +44.56% |
| Graham-Dodd Method(GD) | $38.40 | -94.39% |
| Graham Formula(GF) | $937.40 | +36.85% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $26.56 | $40.34 | $16.40 | $0.80 | $40.90 |
| 2012 | $39.89 | $48.08 | $7.38 | $0.60 | $4.20 |
| 2013 | $41.74 | $56.32 | $7.92 | $5.70 | $35.30 |
| 2014 | $54.08 | $42.47 | $6.74 | $0.00 | $0.00 |
| 2015 | $62.97 | $53.39 | $4.25 | $0.00 | $17.90 |
| 2016 | $73.17 | $58.50 | $6.50 | $0.00 | $29.50 |
| 2017 | $64.99 | $49.57 | $6.18 | $0.00 | $0.00 |
| 2018 | $112.21 | $82.48 | $11.36 | $0.00 | $6.00 |
| 2019 | $109.37 | $84.74 | $3.28 | $0.00 | $46.80 |
| 2020 | $151.19 | $111.26 | $14.11 | $0.00 | $96.00 |
| 2021 | $238.29 | $140.11 | $76.34 | $0.00 | $112.40 |
| 2022 | $301.90 | $166.34 | $47.56 | $0.00 | $49.00 |
| 2023 | $668.58 | $323.49 | $126.76 | $0.00 | $124.60 |
| 2024 | $733.16 | $411.64 | $366.12 | $0.00 | $364.00 |
| 2025 | $790.00 | $485.04 | $861.35 | $38.40 | $937.40 |
AI valuation
Our deep-learning model estimates Eli Lilly and Company's (LLY.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $387.50
- Current price
- $685.00
- AI upside
- -43.43%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$990.27
+44.56% upside
Graham-Dodd
$38.40
-94.39% upside
Graham Formula
$937.40
+36.85% upside
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- CEO
- David A. Ricks
- Employees
- 47K
- Beta
- 0.39
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($990.27 ÷ $685.00) − 1 = +44.56% (DCF, example).